



HEDIS® MY 2022-2024 Medi-Cal Measure Rate Comparison

| Measures | HEDIS MY 2022 | HEDIS MY 2023 | HEDIS MY 2024 | HEDIS MY 2024 Percentile | HEDIS MY 2024 Goals | MCAS MPL Measure |
|---|---------------|---------------|---------------|--------------------------|---------------------|------------------|
| Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA) | 72.61% | 72.69% | 51.71% | 10 th ↓↓↓ | 77.21% | |
| Adult Immunization Status (AIS-E) | | | | | | |
| <i>Influenza (Total)</i> | 13.83% | 19.13% | 14.73% | 33.33 rd ↓ | 26.60% | |
| <i>Td/Tdap (Total)</i> | 40.90% | 46.26% | 45.64% | 50 th ↑ | 61.22% | |
| <i>Zoster (Total)</i> | 10.68% | 17.36% | 22.16% | 75 th ↑ | 24.04% | |
| <i>Pneumococcal (66+)</i> | | 60.54% | 63.54% | 75 th ↑ | 71.90% | |
| Adults' Access to Preventive/Ambulatory Health Services (AAP) – Total | 69.26% | 70.66% | 70.66% | 10 th ↓ | 86.38% | |
| Antidepressant Medication Management (AMM) | | | | | | |
| <i>Effective Acute Phase Treatment</i> | 77.78% | 73.30 | 67.33% | 66.67 th ↓ | 76.65% | |
| <i>Effective Continuation Phase Treatment</i> | 63.39% | 56.74 | 49.38% | 33.33 rd ↓ | 60.51% | |
| Appropriate Testing for Children with Pharyngitis (CWP) – Total | 18.34% | 23.50% | 22.90% | <10 th ↔ | 91.30% | |
| Appropriate Treatment for Children with Upper Respiratory Infection (URI) – Total* | 85.23% | 82.65% | 80.82% | 10 th ↔ | 93.88% | |
| Asthma Medication Ratio (AMR) – Total | 65.87% | 64.98% | 62.57% | 33.33 rd ↔ | 76.25% | X |
| Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (AAB) – Total* | 42.26% | 41.93% | 39.20% | <10 th ↔ | 75.42% | |
| Blood Pressure Control for Patients With Diabetes (BPD) | 66.42% | 70.02% | 71.05% | 33.33 rd ↔ | 78.83% | |
| Breast Cancer Screening (BCS-E) | 58.48% | 62.39% | 63.83% | 75 th ↑ | 66.31% | X |
| Cardiac Rehabilitation (CRE) | | | | | | |
| <i>Initiation</i> | 1.18% | 0.96 | 0.70% | 10 th ↔ | 12.79% | |
| <i>Engagement 1</i> | 0.79% | 0.85 | 0.50% | 10 th ↔ | 11.62% | |
| <i>Engagement 2</i> | 0.79% | 1.01 | 0.75% | 10 th ↔ | 8.63% | |
| <i>Achievement</i> | 0.07% | 0.48% | 0.25% | 25 th ↔ | 3.86% | |

| Measures | HEDIS MY 2022 | HEDIS MY 2023 | HEDIS MY 2024 | HEDIS MY 2024 Percentile | HEDIS MY 2024 Goals | MCAS MPL Measure |
|---|---------------|---------------|---------------|--------------------------|---------------------|------------------|
| Cardiovascular Monitoring for People with Cardiovascular Disease and Schizophrenia (SMC) | 83.72% | 84.39% | 88.20% | 75 th ↔ | 89.19% | |
| Cervical Cancer Screening (CCS) | 56.97% | 65.93% | 57.45% | 33.33 rd ↓ | 68.16% | X |
| Cervical Cancer Screening (CCS-E) | | 55.03% | 53.98% | 50 th ↔ | 64.21% | |
| Child & Adolescent Well-Care Visits (WCV) | 46.78% | 51.49% | 55.84% | 50 th ↔ | 67.63% | X |
| Childhood Immunization Status (CIS) | | | | | | |
| Combination 3 | 50.49% | 53.52 | 61.31% | 10 th ↔ | 75.67% | |
| Combination 10 | 22.95% | 22.99% | 28.47% | 33.33 rd ↑ | 39.89% | X |
| Childhood Immunization Status (CIS-E) | | | | | | |
| Combination 3 | 50.49% | 51.77% | 55.83% | 25 th | 70.12% | |
| Combination 10 | 22.95% | 22.24% | 21.30% | 25 th | 34.79% | |
| Chlamydia Screening in Women (CHL) – Total | 64.88% | 67.93% | 70.49% | 66.67 th ↔ | 70.67% | X |
| Controlling High Blood Pressure (CBP) | 65.32% | 67.55% | 71.86% | 66.67 th ↔ | 75.43% | X |
| Colorectal Cancer Screening (COL-E) | 39.73% | 45.99% | 50.11% | 75 th | 53.31% | |
| Depression Remission or Response for Adolescents and Adults (DRR-E) | | | | | | |
| Follow-Up PHQ-9 | 66.67% | 51.80% | 59.75% | 95 th ↑ | 48.14% | |
| Depression Remission | 11.11% | 16.70% | 20.61% | 95 th ↑ | 15.75% | |
| Depression Response | 11.11% | 23.37% | 28.19% | 95 th ↑ | 21.32% | |
| Depression Screening and Follow-Up for Adolescents and Adults (DSF-E) | | | | | | |
| Depression Screening | 2.06% | 4.46% | 11.23% | 75 th ↑ | 18.24% | |
| Follow-Up on Positive Screen | 58.46% | 67.90% | 67.09% | 33.33 rd ↔ | 85.76% | |
| Developmental Screening in the First Three Years of Life (DEV) | 40.69% | 53.44% | 61.49% | No Benchmark Available | | X |
| Diabetes Monitoring for People with Diabetes and Schizophrenia (SMD) | 81.38% | 81.91% | 81.56% | 75 th ↓↓ | 81.95% | |
| Diabetes Screening for People with Schizophrenia or Bipolar Disorder who are Using Antipsychotic Medication (SSD) | 76.27% | 78.21% | 79.21% | 10 th ↔ | 87.47% | |
| Eye Exam for Patients With Diabetes (EED) | 55.23% | 61.92% | 65.69% | 66.67 th ↔ | 68.61% | |

| Measures | HEDIS MY 2022 | HEDIS MY 2023 | HEDIS MY 2024 | HEDIS MY 2024 Percentile | HEDIS MY 2024 Goals | MCAS MPL Measure |
|--|---------------|---------------|---------------|--------------------------|---------------------|------------------|
| Diagnosed Mental Health Disorders (DMH) | 21.64% | 22.93% | 23.18% | 25 th ↔ | 42.38% | |
| Diagnosed Substance Use Disorder (DSU) | | | | | | |
| <i>Alcohol</i> | 2.07% | 1.90% | 2.20% | 33.33 rd ↔ | 4.66% | |
| <i>Opioid</i> | 1.10% | 1.14% | 1.27% | 25 th ↔ | 5.25% | |
| <i>Other or Unspecified</i> | 2.85% | 2.71% | 2.82% | 33.33 rd ↔ | 6.86% | |
| <i>Any</i> | 4.97% | 4.76% | 5.22% | 25 th ↔ | 11.94% | |
| Follow-Up Care for Children Prescribed ADHD Medication (ADD-E) | | | | | | |
| <i>Initiation Phase</i> | 46.28% | 43.44 | 68.38% | 95 th ↑↑↑ | 57.29% | |
| <i>Continuation & Maintenance Phase</i> | 55.20% | 46.57% | 75.38% | 95 th ↑↑↑ | 63.49% | |
| Follow-Up after Emergency Department Visit for Substance Use (FUA) | | | | | | |
| <i>Total - 7- Day Follow-Up</i> | 20.92% | 25.05% | 27.03% | 50 th ↔ | 39.38% | |
| <i>Total - 30-Day Follow-Up</i> | 38.27% | 37.53% | 39.93% | 50 th ↔ | 53.27% | X |
| Follow-Up after Emergency Department Visit for Mental Illness (FUM) | | | | | | |
| <i>Total - 7- Day Follow-Up</i> | 41.72% | 48.37% | 42.94% | 50 th ↓ | 62.06% | |
| <i>Total - 30-Day Follow-Up</i> | 59.48% | 65.71% | 64.10% | 66.67 th ↓ | 74.67% | X |
| Glycemic Status Assessment for Patients With Diabetes (GSD) | | | | | | |
| <i>Glycemic Status >9.0%[^]</i> | 36.74% | 32.68% | 32.36% | 33.33 rd ↓ | 23.60% | X |
| <i>Glycemic Status <8.0%</i> | 56.20% | 57.25% | 59.61% | 33.33 rd ↔ | 60.58% | |
| Immunizations for Adolescents (IMA) | | | | | | |
| <i>Meningococcal</i> | 77.37% | 75.43% | 72.74% | 10 th ↓ | 90.51% | |
| <i>Tdap/Td</i> | 91.24% | 88.32% | 86.69% | 50 th ↓ | 92.70% | |
| <i>HPV</i> | 35.52% | 40.39% | 40.20% | 50 th ↓ | 53.28% | |
| <i>Combination 1</i> | 76.89% | 73.97% | 71.63% | 10 th ↓ | 89.78% | |
| <i>Combination 2</i> | 30.41% | 37.96% | 38.88% | 33.33 rd ↔ | 52.31% | X |
| Immunizations for Adolescents (IMA-E) | | | | | | |
| <i>Combination 1</i> | 72.92% | 72.87% | 71.63% | 10 th | 87.53% | |
| <i>Combination 2</i> | 34.41% | 37.50% | 38.88% | 66.67 th | 47.16% | |
| Lead Screening in Children (LSC) | 52.07% | 52.39% | 58.95% | 10 th ↔ | 82.86% | X |
| Kidney Health Evaluation for Patients with Diabetes (KED) | 45.47% | 48.27% | 57.95% | 90 th ↑ | 48.71% | |
| Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E) | | | | | | |
| <i>Blood Glucose Testing (Total)</i> | 56.01% | 55.84% | 55.15% | 33.33 rd ↔ | 72.05% | |
| <i>Cholesterol Testing (Total)</i> | 36.48% | 37.62% | 39.17% | 50 th ↔ | 57.50% | |
| <i>Blood Glucose and Cholesterol Testing (Total)</i> | 36.01% | 37.03% | 38.29% | 50 th ↔ | 55.96% | |
| Pharmacotherapy for Opioid Use Disorder (POD) – Total | 17.44% | 20.30% | 15.85% | 10 th ↔ | 36.44% | |

| Measures | HEDIS MY 2022 | HEDIS MY 2023 | HEDIS MY 2024 | HEDIS MY 2024 Percentile | HEDIS MY 2024 Goals | MCAS MPL Measure |
|---|---------------|---------------|---------------|--------------------------|---------------------|------------------|
| Pharmacotherapy Management of COPD Exacerbation (PCE) | | | | | | |
| <i>Systemic Corticosteroid</i> | 77.35% | 79.58% | 60.77% | 10 th ↓↓ | 81.76% | |
| <i>Bronchodilator</i> | 89.43% | 90.99% | 82.80% | 33.33 rd ↓↓ | 91.01% | |
| Plan All-Cause Readmissions (PCR)^ | 0.88 | 0.8969 | 0.9844 | 75 th ↓ | 0.9177 | |
| Postpartum Depression Screening and Follow-Up (PDS-E) | | | | | | |
| <i>Depression Screening</i> | 1.32% | 12.86% | 11.18% | 66.67 th ↓ | 29.75% | |
| <i>Follow-Up on Positive Screen</i> | 81.16% | 67.92% | 75.68% | 50 th ↔ | 87.34% | |
| Prenatal and Postpartum Care (PPC) | | | | | | |
| <i>Timeliness of Prenatal Care</i> | 88.15% | 86.74% | 88.85% | 66.67 th ↑ | 91.97% | X |
| <i>Postpartum Care</i> | 79.63% | 81.72% | 81.92% | 33.33 rd ↓ | 88.32% | X |
| Prenatal Depression Screening and Follow-Up (PND-E) | | | | | | |
| <i>Depression Screening</i> | 2.79% | 16.04 | 15.90% | 50 th ↓ | 41.53% | |
| <i>Follow-Up on Positive Screen</i> | 57.43% | 57.39% | 64.47% | 75 th ↑ | 70.37% | |
| Prenatal Immunization Status (PRS-E) | | | | | | |
| <i>Influenza</i> | 18.08% | 20.97% | 17.69% | 25 th ↔ | 37.11% | |
| <i>Tdap</i> | 44.49% | 46.21% | 46.74% | 25 th ↔ | 76.01% | |
| <i>Combination</i> | 14.48% | 16.90% | 14.45% | 25 th ↓ | 34.91% | |
| Social Need Screening and Intervention (SNS-E) | N/A | 0.00% | 0.00% | No Benchmark Available | | |
| Statin Therapy for Patients with Cardiovascular Disease (SPC) | | | | | | |
| <i>Received Statin Therapy</i> | 80.74% | 82.59% | 82.84% | 33.33 rd ↔ | 86.40% | |
| <i>Adherence 80%</i> | 80.70% | 78.58% | 72.50% | 33.33 rd ↓ | 82.65% | |
| Statin Therapy for Patients with Diabetes (SPD) | | | | | | |
| <i>Received Statin Therapy</i> | 70.11% | 70.95% | 72.65% | 66.67 th ↔ | 73.76% | |
| <i>Adherence 80%</i> | 76.84% | 75.92% | 69.22% | 33.33 rd ↓ | 80.89% | |
| Topical Fluoride for Children (TFL-CH) | 18.46% | 19.35% | 23.38% | No Benchmark Available | | X |
| Unhealthy Alcohol Use Screening and Follow-Up (ASF-E) | | | | | | |
| <i>Unhealthy Alcohol Use Screening</i> | 0.00% | 0.00% | 0.00% | 33.33 rd ↔ | 5.25% | |
| <i>Alcohol Counseling or Other Follow-up Care</i> | N/A | N/A | N/A | No Benchmark Available | | |
| Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) – Total | 47.96% | 47.94% | 64.22% | 50 th ↑↑ | 75.82% | |
| Use of Imaging Studies in Low Back Pain (LBP)* | 75.90% | 73.12% | 72.27% | 50 th ↓ | 78.08% | |
| Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E) – Total | 6.68% | 13.81% | 12.97% | 75 th ↔ | 21.31% | |
| Weight Assessment, Counseling for Nutrition and Physical Activity for Children (WCC) | | | | | | |
| <i>BMI</i> | 82.22% | 89.61% | 90.40% | 66.67 th ↔ | 91.97% | |
| <i>Counseling for Nutrition</i> | 80.37% | 82.44% | 83.20% | 75 th ↔ | 85.64% | |
| <i>Counseling for Physical Activity</i> | 79.63% | 82.08% | 84.00% | 90 th ↑ | 83.70% | |

| Measures | HEDIS MY 2022 | HEDIS MY 2023 | HEDIS MY 2024 | HEDIS MY 2024 Percentile | HEDIS MY 2024 Goals | MCAS MPL Measure |
|---|---------------|---------------|---------------|--------------------------|---------------------|------------------|
| Well-Child Visits in the First 30 Months of Life (W30) | | | | | | |
| <i>Well-Child Visits in the First 15 Months</i> | 55.79% | 59.95% | 60.77% | 33.33 rd ↔ | 71.71% | X |
| <i>Well-Child Visits for Age 15 Months – 30 Months</i> | 62.93% | 67.15% | 70.83% | 33.33 rd ↔ | 82.12% | X |

Source: 2024 Health Plan Ratings Percentiles and Benchmarks and 2024 NCQA Quality Compass National Benchmarks
Benchmark used for MY 2024 goals reflect the 90th percentile

^ Lower Rate is Better

* Reflects an inverted rate

N/A: Not available due to changes in reporting stratification or newly reported measure.

Performance Summary Keys:

| | |
|---|---|
| ↓ | Indicates a decrease in the percentile ranking as compared to the previous measurement year. Each arrow down reflects a level of change in the percentile ranking. (e.g. a measure that went from the 75th percentile to the 50th percentile will display one down arrow) |
| ↑ | Indicates an increase in the percentile ranking as compared to the previous measurement year. Each arrow up reflects a level of change in the percentile ranking. (e.g. a measure that went from the 25th percentile to the 75th percentile will display two up arrows) |
| ↔ | Indicates no change in the percentile ranking as compared to the previous measurement year. |